Exosomes from stem cells for NASH treatment, patent granted

ChangeBridge: Patent Grants - Biotech (C12N)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted Patent US12594303B2 to BREXOGEN INC. on April 7, 2026. The patent covers pharmaceutical compositions comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells for preventing or treating non-alcoholic steatohepatitis (NASH). The patent application was filed August 12, 2020, and contains 2 claims.

View original document View source feed page

What changed

USPTO granted Patent US12594303B2 to BREXOGEN INC. (inventors: Sue Kim, Seulki Lee, Jimin Kim) covering a pharmaceutical composition using exosomes isolated from induced pluripotent stem cell-derived mesenchymal stem cells for NASH treatment. The composition demonstrated improved efficacy compared to conventional mesenchymal stem cell-derived exosomes. Application No. 17621743 was filed August 12, 2020, and the patent includes 2 claims.

This patent grant establishes intellectual property rights for BREXOGEN INC. in the NASH treatment space using stem cell-derived exosomes. Other entities developing similar exosome-based NASH therapies should conduct freedom-to-operate analyses to assess potential infringement risks. Patent holders should record this grant in relevant IP databases and consider licensing opportunities.

Source document (simplified)

← USPTO Patent Grants

Composition comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell progenitor for prevention or treatment of non-alcoholic steatohepatitis

Grant US12594303B2 Kind: B2 Apr 07, 2026

Assignee

BREXOGEN INC.

Inventors

Sue Kim, Seulki Lee, Jimin Kim

Abstract

The present disclosure relates to a pharmaceutical composition for prevention or treatment of non-alcoholic steatohepatitis, the composition comprising, as an active ingredient, exosomes isolated from induced pluripotent stem cell-derived mesenchymal stem cells which have been or have not been treated with a pretreatment material. The exosomes of the present disclosure exhibit a more improved effect of preventing or treating non-alcoholic steatohepatitis, compared to those isolated from conventional mesenchymal stem cells and as such, can be advantageously used for relevant research and development, and productization.